This regulatory context applies broadly across the telehealth GLP-1 industry and is not specific to MEDVi
A one-size-fits-all approach doesnt work when it comes to weight loss assisted by GLP-1 drugs
participant advisory boards and consulting for Altimmune, Becton Dickinson, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly and Company, Gilead, Intercept, Merck, Novo Nordisk, Pfizer and Sanofi
Quality and regulation are major concernscompounded drugs are not FDA-approved
Ozempic for type 2 diabetes) see NICE Technology Appraisal TA875 Tirzepatide (Mounjaro) licensed by the MHRA for type 2 diabetes and, subject to applicable NICE guidance and local formulary decisions, for weight management in adults with obesity Liraglutide (Saxenda for weight management
El intervalo vara segn el caso